Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

Stayble Therapeutics: BioStock: Stayble did not reach the primary endpoint in phase IIb

Stayble Therapeutics

Stayble Therapeutics recently announced that the company's phase IIb study did not meet the primary endpoint. The drug candidate STA363 did not show a statistically significant reduction in pain compared to placebo after 6 months. The company now plans to continue evaluating top-line data from the study to create a better understanding of the results. 

Read the full article at biostock.se:

https://www.biostock.se/en/2023/11/stayble-did-not-reach-the-primary-endpoint-in-phase-iib/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.